Industrial Policy & Trade Monitor· 2667 actions· ✨ 89 recent

USTR formally initiated the second statutorily mandated four-year review of its Section 301 investigation into China's acts, policies, and practices related to technology transfer, intellectual property, and innovation (Federal Register 2026-08806, published May 6, 2026). The review covers tariff actions imposed on approximately $300 billion of Chinese goods across Lists 1–4B (25% on most lists; 7.5% on List 4A) and will determine whether those actions should be continued, modified, or terminated. Interested parties may file continuation requests in two 60-day windows: May 7–July 5, 2026 (for the July 6, 2018 action) and June 24– August 22, 2026 (for the August 23, 2018 action). DISTINCT from the March 2026 Section 301 excess-capacity investigations (which target 16 economies on overcapacity sectors) and from the June 2026 Section 301 forced-labor enforcement action (60 economies); this review is China-specific, IP/TT-focused, and mandated by the original Biden-era statutory clock under Section 304(c) of the Trade Act of 1974.

The US Department of Commerce published its final affirmative determination of sales at less-than-fair-value in the antidumping investigation of animal feed-grade L-lysine (lysine) from China (case A-570-215) on 23 July 2026, following a preliminary determination published 6 March 2026 (91 FR 11030). Commerce found a China-wide weighted-average dumping margin of 139.83% (cash deposit rate 139.65% after subsidy-offset adjustment), based on adverse facts available after Commerce found Zhengzhou Longgu Trading Co., the sole company with a calculated margin, and the Eppen Group group of producers/exporters uncooperative and ineligible for a separate rate in the final determination. A group of separate-rate companies — including Anhui BBCA Biochemical, Heilongjiang Wanlirunda Biotechnology, and others exporting through trading intermediaries such as Agromate Sg, Ainore (Tianjin), and Aollen Biotech — received a 73.55% dumping margin (73.37% cash deposit rate). The order covers lysine regardless of form (HCl, sulfate, liquid) under HTSUS 2922.41.0090 and related subheadings. A companion countervailing-duty investigation (preliminary 22 January 2026, 91 FR 2745) was finalized the same day; suspension of liquidation runs from 6 March 2026, with a final AD order contingent on an ITC injury determination due within 45 days of the final LTFV finding.

Brazil's Foreign Trade Chamber executive committee (GECEX) issued Resolution No. 852, dated 4 February 2026 and published in the Diário Oficial da União on 5 February 2026, amending Annex VI of Resolução Gecex nº 272/2021 — the instrument that adapted Brazil's Common Mercosur Nomenclature (NCM) and Common External Tariff (TEC) to the 2022 Harmonized System revision. The measure realigns applied tariffs on roughly 1,249 NCM codes under the IT/telecom (LEBIT) and capital-goods (BK) special-tariff exception lists, per secondary reporting raising codes currently taxed below a 7.2% floor up to that rate, with other affected lines moving to higher bracket rates (reported figures include 12.6%, 20%, and other tiers depending on product). Aeronautical-sector products are explicitly excluded from the recomposition (Art. 2). Global Trade Alert classifies the measure as a "Red" (trade-restrictive) import tariff intervention.

The US Department of Commerce published its final affirmative countervailing-duty (CVD) determination on animal feed-grade L-lysine from China (case C-570-216) on 23 July 2026, the companion subsidy proceeding to the parallel antidumping case (A-570-215) finalized the same day. Commerce found Heilongjiang Wanlirunda Biotechnology Co., Ltd. and Shouguang Golden-land Industry & Trading Co., Ltd. received countervailable subsidies at 82.11%, while Inner Mongolia Eppen Biotech Co., Ltd. and all other Chinese producers/exporters were assigned a 48.21% subsidy rate. The preliminary CVD determination, published 22 January 2026, set the initial cash-deposit rates and suspension of liquidation; the final determination confirmed and aligned the case with the AD final determination for a joint ITC injury vote.